Nomir Medical to Present Positive In Vitro Data on Antibacterial Properties of its Noveon(R) Dual-Wavelength Optical Energy Device

WALTHAM, Mass.--(BUSINESS WIRE)--Nomir Medical Technologies, a leader in the development of optical energy technologies for anti-infective medical applications, announced today that the Company will present an abstract detailing two years of successful scientific research into the antibacterial action spectrum of its Noveon® dual-wavelength optical antimicrobial system. The antimicrobial action spectrum experiments demonstrate that the Noveon patented and proprietary 870nm/930nm wavelengths are more effective at inactivating pathogens than other near-infrared wavelength combinations that were tested. The Noveon is designed to cause photo-damage in bacterial and fungal pathogens and is the first known device to do so at temperatures that are safe to normal and healthy tissue.